DE102009047243A1 - Monospezifische Polypeptidreagenzien - Google Patents

Monospezifische Polypeptidreagenzien Download PDF

Info

Publication number
DE102009047243A1
DE102009047243A1 DE102009047243A DE102009047243A DE102009047243A1 DE 102009047243 A1 DE102009047243 A1 DE 102009047243A1 DE 102009047243 A DE102009047243 A DE 102009047243A DE 102009047243 A DE102009047243 A DE 102009047243A DE 102009047243 A1 DE102009047243 A1 DE 102009047243A1
Authority
DE
Germany
Prior art keywords
seq
fusion polypeptide
igg
domain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102009047243A
Other languages
German (de)
English (en)
Inventor
Robert Poppe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
POPPE, ROBERT, DR., DE
Original Assignee
Orgentec Diagnostika GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orgentec Diagnostika GmbH filed Critical Orgentec Diagnostika GmbH
Priority to DE102009047243A priority Critical patent/DE102009047243A1/de
Priority to PCT/EP2010/068134 priority patent/WO2011064257A2/de
Priority to DK10798744.8T priority patent/DK2504359T3/da
Priority to US13/512,206 priority patent/US9163079B2/en
Priority to EP10798744.8A priority patent/EP2504359B1/de
Priority to AU2010323144A priority patent/AU2010323144B2/en
Priority to JP2012540419A priority patent/JP2013511966A/ja
Priority to CA2782016A priority patent/CA2782016C/en
Publication of DE102009047243A1 publication Critical patent/DE102009047243A1/de
Priority to US14/848,636 priority patent/US9815891B2/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE102009047243A 2009-11-27 2009-11-27 Monospezifische Polypeptidreagenzien Withdrawn DE102009047243A1 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE102009047243A DE102009047243A1 (de) 2009-11-27 2009-11-27 Monospezifische Polypeptidreagenzien
PCT/EP2010/068134 WO2011064257A2 (de) 2009-11-27 2010-11-24 Monospezifische polypeptidreagenzien
DK10798744.8T DK2504359T3 (da) 2009-11-27 2010-11-24 Monospecifikke polypeptidreagenser
US13/512,206 US9163079B2 (en) 2009-11-27 2010-11-24 Monospecific polypeptide reagents
EP10798744.8A EP2504359B1 (de) 2009-11-27 2010-11-24 Monospezifische polypeptidreagenzien
AU2010323144A AU2010323144B2 (en) 2009-11-27 2010-11-24 Monospecific polypeptide reagents
JP2012540419A JP2013511966A (ja) 2009-11-27 2010-11-24 単一特異性ポリペプチド試薬
CA2782016A CA2782016C (en) 2009-11-27 2010-11-24 Monospecific polypeptide reagents
US14/848,636 US9815891B2 (en) 2009-11-27 2015-09-09 Monospecific polypeptide reagents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102009047243A DE102009047243A1 (de) 2009-11-27 2009-11-27 Monospezifische Polypeptidreagenzien

Publications (1)

Publication Number Publication Date
DE102009047243A1 true DE102009047243A1 (de) 2011-06-01

Family

ID=43589669

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102009047243A Withdrawn DE102009047243A1 (de) 2009-11-27 2009-11-27 Monospezifische Polypeptidreagenzien

Country Status (8)

Country Link
US (2) US9163079B2 (cg-RX-API-DMAC7.html)
EP (1) EP2504359B1 (cg-RX-API-DMAC7.html)
JP (1) JP2013511966A (cg-RX-API-DMAC7.html)
AU (1) AU2010323144B2 (cg-RX-API-DMAC7.html)
CA (1) CA2782016C (cg-RX-API-DMAC7.html)
DE (1) DE102009047243A1 (cg-RX-API-DMAC7.html)
DK (1) DK2504359T3 (cg-RX-API-DMAC7.html)
WO (1) WO2011064257A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
WO2015153997A2 (en) * 2014-04-04 2015-10-08 Oncomed Pharmaceuticals, Inc. Notch3 antibodies and uses thereof
HUE065861T2 (hu) * 2016-08-26 2024-06-28 Sanofi Sa Szelektív könnyûlánc-párosítást elõsegítõ multispecifikus antitestek
AU2017350947B2 (en) * 2016-10-28 2024-02-15 Washington University Anti-ApoE antibodies
CN113518823B (zh) * 2019-01-07 2025-05-02 托马斯杰斐逊大学 多功能的融合蛋白及其用途
ES3031566T3 (en) 2019-06-24 2025-07-09 Univ Stuttgart Tnfr2 agonists with improved stability

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
EP1018019B1 (en) 1996-01-23 2003-08-20 Abbott Laboratories Reagents for use as calibrators and controls
WO2006117782A2 (en) * 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69726003T2 (de) * 1996-07-16 2004-08-26 Andreas Plückthun Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
US6151296A (en) 1997-06-19 2000-11-21 Qualcomm Incorporated Bit interleaving for orthogonal frequency division multiplexing in the transmission of digital signals
EP1190061A1 (en) 1999-06-07 2002-03-27 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
DE10001372A1 (de) 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
ES2335232T3 (es) * 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
EP1757622B1 (en) * 2005-08-26 2009-12-23 PLS Design GmbH Bivalent IgY antibody constructs for diagnostic and therapeutic applications
EP1962961B1 (en) * 2005-11-29 2013-01-09 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
US8273030B2 (en) 2005-12-01 2012-09-25 Atcor Medical Pty Ltd Method of estimating pulse wave velocity
ATE509033T1 (de) 2006-03-20 2011-05-15 Univ California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
CA2682605A1 (en) * 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
US20080283653A1 (en) * 2007-04-20 2008-11-20 Invista North America Sarl Compact continuous over end take-off (oeto) creel with tension control
CA2689895A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Non-glycosylated recombinant monovalent antibodies
EP2116555A1 (en) * 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
EP1018019B1 (en) 1996-01-23 2003-08-20 Abbott Laboratories Reagents for use as calibrators and controls
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
WO2006117782A2 (en) * 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
Barthelemy et al. (2007) J. Biol. Chem. 283: 3639-54
Berman et al. (2003), Nature Structural Biology 10: 980
Boehm et al. (1999) J. Mol. Biol. 286: 1421-1447
DÜBEL,Stefan,u.a.:Rekombinante Antikörper.Biol. Unserer Zeit,34. Jahrgang 2004,Nr.6,Wiley-VCH Verlag GmbH,S.717-722 Abstr. Fig.1
DÜBEL,Stefan,u.a.:Rekombinante Antikörper.Biol. Unserer Zeit,34. Jahrgang 2004,Nr.6,Wiley-VCH Verlag GmbH,S.717-722 bstr. Fig.1$ *
Hollinger et al. (1993), PNAS 90: 6444-48
Hu et al. (1996), Cancer Res 56: 3055-61
Hu. et al. (1996), Cancer Research 56: 3055-61
Ichikawa et al. (1999), Arthritis and Rheumatism 42: 2461
Nieba et al. (1997), Protein Eng 10: 435-44
Perkins et al. (1991). J. Mol. Biol. 221: 1345-1366
Read et al. (2007), Appl. Environ. Microbiol. 73: 5088-96
TRINH,Ryan,et.al.:Optimization of codon pair use within the (GGGGS)3 linker sequence results in enhanced protein expression.Molecular Immonulogy 40,2004,S.372-379 Abb.4
TRINH,Ryan,et.al.:Optimization of codon pair use within the (GGGGS)3 linker sequence results in enhanced protein expression.Molecular Immonulogy 40,2004,S.372-379 bb.4$ *

Also Published As

Publication number Publication date
US9815891B2 (en) 2017-11-14
JP2013511966A (ja) 2013-04-11
US20160046703A1 (en) 2016-02-18
EP2504359A2 (de) 2012-10-03
AU2010323144B2 (en) 2013-11-07
WO2011064257A2 (de) 2011-06-03
CA2782016A1 (en) 2011-06-03
AU2010323144A1 (en) 2012-07-12
DK2504359T3 (da) 2016-07-25
WO2011064257A3 (de) 2011-08-11
US20120276099A1 (en) 2012-11-01
EP2504359B1 (de) 2016-03-23
US9163079B2 (en) 2015-10-20
CA2782016C (en) 2020-01-07

Similar Documents

Publication Publication Date Title
EP2504359B1 (de) Monospezifische polypeptidreagenzien
AU627183B2 (en) Method for producing recombinant dna proteins
DE69232604T2 (de) Antikörperkonstrukte
US5132405A (en) Biosynthetic antibody binding sites
US5091513A (en) Biosynthetic antibody binding sites
US6207804B1 (en) Genetically engineered antibody analogues and fusion proteins thereof
CN103429619A (zh) 双特异性和单特异性、不对称抗体和其制备方法
JP2005537009A (ja) 免疫系分子をヒト化する方法
TW202108613A (zh) 用於多聚化蛋白質及其分離的變異區域
CN115380210A (zh) 含多特异性抗原结合分子的组合物中的杂质分子的分析方法
US12000839B2 (en) Methods for characterizing disulfide bonds
CN116964084A (zh) 双特异性抗体
US20260009804A1 (en) Antibodies that bind to natively folded myocilin
DE202018006693U1 (de) Target-Detektion mit einem monovalenten Antikörper
KR20240007767A (ko) CLDN18.2에 대한 단클론 항체 및 이의 Fc 조작된 형태
CA3189938A1 (en) Antibody specific for mucin-1 and methods of use thereof
KR20190075071A (ko) 프래그먼트 항체 및 당해 프래그먼트 항체를 이용하는 단백질의 결정화 방법
WO2014148444A1 (ja) 抗イヌＩｇＥモノクローナル抗体並びに抗イヌＩｇＥモノクローナル抗体の重鎖可変領域及び軽鎖可変領域
CN118440194B (zh) 用于检测鼠白介素-2的抗体、抗体对及检测试剂或试剂盒
WO2026025029A1 (en) Method for selectively controlling the generation of degradants from a biological product exposed to a stress condition
EP3201328A1 (de) Fusionsprotein und aufreinigungsverfahren
CN120718146A (zh) 抗人TNF-β的单克隆抗体及其应用

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
R081 Change of applicant/patentee

Owner name: POPPE, ROBERT, DR., DE

Free format text: FORMER OWNER: ORGENTEC DIAGNOSTIKA GMBH, 55129 MAINZ, DE

R082 Change of representative

Representative=s name: WEICKMANN & WEICKMANN PATENTANWAELTE - RECHTSA, DE

Representative=s name: WEICKMANN & WEICKMANN PATENT- UND RECHTSANWAEL, DE

R005 Application deemed withdrawn due to failure to request examination